The target INR range for patients on warfarin therapy varies depending on their condition but is typically between 2.0 and 3.0.

Frequency of testing depends on individual patient needs, but initially, it may be done weekly or bi-weekly until stable, then less frequently thereafter.

Yes, the PT / INR Test can help diagnose various clotting disorders, including those related to liver disease or genetic clotting factor deficiencies.

Medications, dietary changes, liver function, and underlying health conditions can all influence PT / INR results.

Yes, the PT / INR Test is a safe and standard diagnostic procedure used worldwide to monitor blood clotting ability and adjust anticoagulant therapy.

Benefits include accurate diagnosis, targeted treatment of bladder conditions, and minimal invasiveness with quick recovery.

G6PD deficiency is a genetic disorder that affects the red blood cells, making them more vulnerable to breaking down prematurely.

Symptoms such as fatigue, jaundice, dark urine, or a family history of G6PD deficiency may indicate the need for this test.

The G6PD test is a simple blood test with minimal risks, similar to any standard blood draw.

Management includes avoiding triggers such as certain medications, foods, and infections that can cause hemolysis.

Early detection in newborns can prevent severe jaundice and related complications by guiding appropriate care and dietary adjustments.